Akebia Therapeutics, Inc. fell 38.8% on Thursday, November 5, 2026, on 17,152,491 shares, 2.1 times its average daily volume. Headlines around the move:
Akebia Therapeutics, Inc. (AKBA:NASDAQ) closed at $0.426 on November 5, 2026, down 38.75% on the day. The stock trades 79.8% below its 52-week high of $2.11 and 0.4% above its 52-week low of $0.424. Over the past year, it lost 78.8%. Akebia Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 5, 2025, AKBA closed higher on 111 days (44%). Its best day was October 28, 2026 (+15.91%) and its worst was November 5, 2026 (-38.75%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 2 times.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Find more stocks like AKBA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.